Recent publications and conference presentations from VHsquared include:
November 25, 2018 – A discussion of the formulation of V565 required to provide gastro-protection and enable optimal delivery to the lower intestinal tract in monkeys was published in Drug Development and Industrial Pharmacy
Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys
PEGS Europe Protein and Antibody Engineering Summit, November 12-16 2018, Lisbon, Portugal
Oral presentation – V565 Is an Orally Administered, Protease-Resistant, Anti-TNF Domain Antibody for the Treatment of Inflammatory Bowel Disease (Contact us here for more information.)
Falk Foundation Symposium 213, October 5 – 6, Milan, Italy – Tailored Therapies for IBD: A Look into the Future
V565, a Novel Oral l Anti -TNF Domain Antibody, Binds to Mucosal Macrophages and T Cells and Reduces Colonic Mucosal Inflammation after 6 Days Oral Dosing to Ulcerative Colitis Patients
The British Society of Gastroenterology Annual Meeting 2018, June 4-7, Liverpool UK – presented as an Abstract of Distinction
V565, a Novel, Oral Anti-TNF Domain Antibody, Reduces Colonic Mucosal Inflammation in Patients with Ulcerative Colitis
11th Annual Proteins and Antibodies Congress, April 16-17 2018, London UK & 17th Annual Pep Talk, January 8-12 2018, San Diego, USA
V565 is a highly potent, orally-delivered, anti-TNFα VorabodyTM that is highly stable during intestinal transit in cynomolgus monkeys
V565, an intestinal protease-stabilised oral anti-TNFα VorabodyTM, inhibits inflammation in ulcerative colitis patients
March 21, 2018 – Preclinical research supporting use of oral anti-TNFα Vorabody V565 in IBD treatment published in Scientific Reports
First full account of V565 preclinical development available in open access journal
Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease
13th Congress of ECCO, February 14-17 2018, Vienna, Austria
Measured and modelled data suggest that oral administration of V565, a novel domain antibody to TNF-alpha, could be beneficial in the treatment of IBD
2017 Antibody Engineering & Therapeutics meeting, December 10-14 2017, San Diego, USA
Predicting intestinal tract luminal concentrations after oral dosing of an anti-TNFα domain antibody engineered for intestinal protease resistance
PEGS Europe Protein and Antibody Engineering Summit, November 13-17 2017, Lisbon, Portugal
Gastrointestinal Stability and Tissue Penetration of V565: a Novel Orally Administered Anti-TNFα Vorabody
Orally delivery of a novel engineered anti-TNFα domain antibody (Vorabody) for the treatment of Intestinal Bowel Disease
25th United European Gastroenterology Week, Oct 28- Nov 1 2017, Barcelona, Spain
Oral presentation – V565, A Novel Oral Domain Antibody to TNF, Reduces Colonic Mucosal Inflammation after 7 Days Oral Dosing to Patients with Ulcerative Colitis. (Contact us here for more information.)
Oral presentation – A Novel Oral Domain Antibody to Tumour Necrosis Factor (TNF), Engineered to be Stable to Intestinal Proteases, Results in High Concentrations of Active Compound Detected in Faeces of Crohn’s Patients After Oral Dosing. (You can read the abstract, OP272 here, or contact us here for more information.)
18th International Congress of Mucosal Immunology, July 19-22 2017, Washington DC, USA
Preclinical assessment of a novel anti-TNFα Vorabody™ as an oral therapy for Crohn’s Disease
Global Conference on Pharmaceutics and Drug Delivery Systems, June 29 – July 1 2017, Valencia Spain
Oral delivery of a novel domain antibody (Vorabody™) for the treatment of Crohn’s Disease
10th Annual Proteins and Antibodies Congress, April 24-25 2017, London UK